This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
ISTH Guidelines on TTP

ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura

The International Society on Thrombosis and Haemostasis (ISTH) has published new clinical practice guidelines for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TTP). Developed in partnership with McMaster University, the ISTH TTP Guidelines are the product of a rigorous, systematic review of evidence by a guideline panel comprised of clinical experts, methodologists and patient representatives.

TTP is a rare, life-threatening thrombotic microangiopathy or blood disorder. In TTP, blood clots form in small blood vessels throughout the body and can limit or block the flow of oxygen-rich blood to the body’s organs, such as the brain, kidneys and heart. This can result in serious health problems. The reported incidence of TTP is two to six cases per million per year and a mortality of 10-20 percent upon proper treatment.

The challenge is that there are a number of conditions that have clinical and laboratory presenting features similar to those of TTP. A number of new therapeutic agents have been developed, requiring detailed guidance to properly manage treatment. The ISTH TTP Guidelines provide important recommendations, which will improve the management of patients with TTP.


Membership Management Software Powered by YourMembership  ::  Legal